Mebutamate (Capla) (2-methyl-2-sec-bytyl-1, 3-propanediol dicarbamate) is a derivative of meprobamate. Its chemical structure differs by the addition of a methyl group on the propyl side chain.
Mebutamate was reported to have a specific and selective action on the hypothalamus and medullary vasomotor control centers, resulting in a hypotensive effect without alteration of cardiac output.1 Reports appeared sporadically in the literature and as exhibits at meetings documenting the antihypertensive action of this agent.2-9 The US Public Health Service Cooperative Study organization (Public Health Service hospitals in Baltimore, Boston, New Orleans, Norfolk, San Francisco, Seattle, and Staten Island) elected to evaluate mebutamate in a double-blind protocol employing home blood pressures, the basic design for which has been published elsewhere.10
Criteria for selection, the pretreatment clinical and laboratory evaluation, and the severity index were identical to the earlier study hereafter referred to as study 1. In brief, the subjects
Evaluation of Antihypertensive TherapyII. Double-Blind Controlled Evaluation of Mebutamate. JAMA. 1965;193(9):727–729. doi:10.1001/jama.1965.03090090033008
Customize your JAMA Network experience by selecting one or more topics from the list below.